Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 2:115:e190361.
doi: 10.1590/0074-02760190361. eCollection 2020.

FLI1 gene influences lesion size and skin test may predict therapeutic response in cutaneous leishmaniasis

Anadilton Santos da Hora  1   2 , Lucas Frederico de Almeida  2 , Tainã Souza do Lago  1   2 , Paulo Roberto Machado  1   2   3 , Léa Cristina Castellucci  1   2   3
Affiliations

FLI1 gene influences lesion size and skin test may predict therapeutic response in cutaneous leishmaniasis

Anadilton Santos da Hora et al. Mem Inst Oswaldo Cruz. .

Abstract

Genes associated with wound healing have been shown to be risk factors for cutaneous leishmaniasis (CL) which is caused by Leishmania braziliensis. In this study, we examined whether the genes previously associated with CL influenced the clinical outcome. Patients were genotyped and retrospectively classified as responders, who were cured with a single course of pentavalent antimony (Sbv), or as refractories, who did not respond to Sbv. Patients characterised as responders showed a stronger response to the leishmanin skin test (LST) when compared to the refractory subjects (p = 0.0003). Furthermore, we observed an association between the FLI1 CC genotype and an increased size of ulcers (p = 0.0170). We suggest that the leishmanin skin test may be a predictive tool for therapeutic outcome and reinforce FLI1 as a potential influencer of susceptibility and lesion size in CL.

PubMed Disclaimer

Figures

None
(A) Induration area (mm) in the skin test of patients classified as refractories or responders according to the treatment with a pentavalent antimony. (B) Lesion size (mm) of patients with leishmaniasis according to the genotypes of the FLI1 gene.
See this image and copyright information in PMC

References

    1. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100(1):S26–S33. - PubMed
    1. Prates FVO, Dourado MEF, Silva SC, Schriefer A, Guimarães LH, Brito MGO. Fluconazole in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis a randomized controlled trial. Clin Infect Dis. 2017;64(1):67–71. - PubMed
    1. Machado PR, Ampuero J, Guimarães LH, Villas boas L, Rocha AT, Schriefer A. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4(12):e912. - PMC - PubMed
    1. Castellucci LC, Almeida LF, Jamieson SE, Fakiola M, Carvalho EM, Blackwell JM. Host genetic factors in American cutaneous leishmaniasis a critical appraisal of studies conducted in an endemic area of Brazil. Mem Inst Oswaldo Cruz. 2014;109(3):279–288. - PMC - PubMed
    1. Sakthianandeswaren A, Curtis JM, Elso C, Kumar B, Baldwin TM, Lopaticki S. Fine mapping of Leishmania major susceptibility locus lmr2 and evidence of a role for Fli1 in disease and wound healing. Infect Immun. 2010;78(6):2734–2744. - PMC - PubMed